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Abstract
A substantial proportion of familial colorectal cancer (CRC) is not a consequence of known susceptibility loci, such as
mismatch repair (MMR) genes, supporting the existence of additional loci. To identify novel CRC loci, we conducted a
genome-wide linkage scan in 356 white families with no evidence of defective MMR (i.e., no loss of tumor expression of
MMR proteins, no microsatellite instability (MSI)-high tumors, or no evidence of linkage to MMR genes). Families were
ascertained via the Colon Cancer Family Registry multi-site NCI-supported consortium (Colon CFR), the City of Hope
Comprehensive Cancer Center, and Memorial University of Newfoundland. A total of 1,612 individuals (average 5.0 per
family including 2.2 affected) were genotyped using genome-wide single nucleotide polymorphism linkage arrays;
parametric and non-parametric linkage analysis used MERLIN in a priori-defined family groups. Five lod scores greater than
3.0 were observed assuming heterogeneity. The greatest were among families with mean age of diagnosis less than 50
years at 4q21.1 (dominant HLOD=4.51, a= 0.84, 145.40 cM, rs10518142) and among all families at 12q24.32 (dominant
HLOD= 3.60, a= 0.48, 285.15 cM, rs952093). Among families with four or more affected individuals and among clinic-based
families, a common peak was observed at 15q22.31 (101.40 cM, rs1477798; dominant HLOD= 3.07, a= 0.29; dominant
HLOD= 3.03, a= 0.32, respectively). Analysis of families with only two affected individuals yielded a peak at 8q13.2 (recessive
HLOD= 3.02, a= 0.51, 132.52 cM, rs1319036). These previously unreported linkage peaks demonstrate the continued utility
of family-based data in complex traits and suggest that new CRC risk alleles remain to be elucidated.
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Introduction
Colorectal cancer (CRC) is the third most common cancer and
the third leading cause of cancer death in the United States.
Approximately 141,210 new cases and 49,380 deaths from CRC
were expected in the United States in 2011 [1]. Family history is a
consistent risk factor [2]; without CRC family history, the lifetime
risk for an individual above the age of 50 years is 5% to 6%, yet
this can be as high as 20% when there are first- or second-degree
relatives with CRC [3–5], and reaches 80% to 100% in familial
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syndromes [6]. Lynch syndrome represents up to 5% of CRCs and
results from germline mutations in one of several DNA mismatch
repair (MMR) genes (MLH1, MSH2, MSH6 and PMS2 [7]. MMR
mutations result in a defective mismatch repair (dMMR) tumor
phenotype manifested by absence of MMR protein expression
[8,9] and DNA microsatellite instability (MSI-H). Segregation
analyses excluding Lynch syndrome families suggest that addi-
tional loci for CRC susceptibility exist [5].
To identify novel loci, case-control association studies and
family-based linkage analyses serve as complementary approaches.
At least fifteen, common low-penetrance risk alleles have emerged
from genome-wide association studies (GWAS) including at 1q41
(rs6691170, DUSP10) [10], 3q26.2 (rs10936599, MYNN) [10],
8q23.3 (rs16892766, EIF3H) [11], 8q24 (rs6983267) [12,13], 9p24
(rs719725) [14], 10p14 (rs10795668) [11], 11q23 (rs3802842) [15],
12q13.13 (rs11169552) [10], 14q22.2 (rs4444235, BMP4) [16],
15q13 (rs4779584) [15], 16q22.1 (rs9929218, CDH1) [16], 18q21
(rs4939827, SMAD7) [17], 19q13.1 (rs10411210, RHPN2), 20p12.3
(rs961253) [16], and 20q13.33 (rs4925386, LAMA5) [10]. Studies
of CRC linkage in multi-case families or affected sibling pairs have
reported evidence of rare, high-risk variants in several genetic
regions including 3q21-24, 7q31, 9q22-31, and 11q23 [18–26].
Most linkage studies to date have utilized fewer than 100 families,
and only two studies excluded dMMR families [18,26].
Here, we describe a genome-wide linkage scan of 356 white
families without evidence of dMMR using family groups defined
by age at diagnosis, ascertainment method, and number of
affected family members. This represents the largest linkage study
of proficient MMR (pMMR) CRC families to date and suggests
novel regions with evidence of high-penetrance loci.
Materials and Methods
Ethics Statement
All participants gave written informed consent. Ontario Cancer
Research Ethics Board, University of Southern California
Institutional Review Board, University of Melbourne Institutional
Review Board, University of Hawaii Institutional Review Board,
Mayo Clinic Institutional Review Board, Fred Hutchinson Cancer
Research Center Institutional Review Board, Memorial University
of Newfoundland Institutional Review Board and City of Hope
Institutional Review Board approved protocols.
Ascertainment and Collection of Families
A total of 578 linkage-informative families were identified
having at least two affected individuals diagnosed with invasive
CRC in sibling, half-sibling, cousin, grand-parental, or avuncular
pairs [27], absence of sequence-confirmed Lynch Syndrome and
MYH-associated polyposis [28], and absence of medical-record-
confirmed familial adenomatous polyposis.
The majority of families (N= 480) were from the Colon Cancer
Family Registry multi-site NCI-supported consortium (Colon
CFR) ascertained between 1997 and 2007 by Cancer Care
Ontario (Toronto, Canada), a University of Southern California
Consortium (Los Angeles, CA), a University of Melbourne
Consortium (Victoria, Australia), the University of Hawaii
(Honolulu, HI), the Mayo Clinic (Rochester, MN), and the Fred
Hutchinson Cancer Research Center (Seattle, WA) [28]. All study
sites ascertained population-based families, although varying
sampling schemes based upon age and/or family history were
used. Clinic-based families were ascertained by the University of
Melbourne Consortium (through family cancer clinics in Adelaide,
Perth, Sydney, Brisbane, and Melbourne, Australia and Auckland,
New Zealand), the University of Southern California Consortium
(through the Cleveland Clinic), and the Mayo Clinic. Epidemio-
logic data, blood samples, tumor blocks, and pathology reports
were collected on all participants with CRC at each site, using
standardized core protocols.
Clinic-based families from a City of Hope consortium (N=59)
were recruited between 1998 and 2005 at the City of Hope
(Duarte, CA), Tufts University (Medford, MA), the University of
Pittsburgh (Pittsburgh, PA), Northwestern University (Chicago,
IL), the University of Wisconsin (Madison, WI), Vanderbilt
University (Nashville, TN), the University of South Florida/
Moffitt Cancer Center (Tampa, FL), Maine Medical Center
(Portland, ME), and Rose Medical Center (Denver, CO). White
CRC cases older than 18 years of age, who had at least one living
sibling diagnosed with CRC, were enrolled. Blood samples,
pathology reports, and a brief questionnaire focused on ethnicity
and family history were collected on all cases.
Population-based and clinic-based families (N= 39) from
Newfoundland and Labrador, Canada were obtained at Memorial
University of Newfoundland as previously described [29,30].
Briefly, pathologically confirmed cases diagnosed under the age of
75 years were enrolled via the provincial tumor registry between
1997 and 2003. Epidemiologic data including family history and
risk factors, blood samples, tumor tissue, and pathology reports
were collected. Clinic-based families were contacted following
referrals to the high-risk cancer clinic of the provincial Medical
Genetics Program.
SNP Genotyping and Quality Control
We genotyped all available affected individuals within each
family, as well as key unaffected individuals, including siblings,
children, and spouses of deceased affected individuals; parents of
affected siblings; grandparents of affected cousins; and other
individuals useful for estimation of phase [31]. Single nucleotide
polymorphism (SNP) genotyping was conducted using the
Affymetrix 10K 2.0 array (Affymetrix, Santa Clara, CA) for 327
families (1,753 individuals) and the Illumina Infinium Linkage 12
bead array (Illumina, San Diego, CA) for 251 families (1,001
individuals) following manufacturers’ protocols [32,33]. A CEU
trio (Coriell Institute for Medical Research, Camden, NJ, USA)
was included in each 96-well plate.
Hardy-Weinberg equilibrium (HWE) testing relied on mean p-
values from exact testing of 100 random samples of one individual
per pedigree. SNPs were excluded with unknown genetic position
(n= 147) (build 36.3), call rate ,95% (n= 1,076), minor allele
frequency (MAF) ,1% (n= 377), HWE p-value,0.001 (n= 17),
duplicate concordance ,95% (n= 10), or Mendelian error in
.2% of families (n = 4). We also excluded SNPs to reduce LD
(r2.0.10) (n = 4,512) in order to minimize false-positive linkage
findings (Table S1) [34]. For 10,091 unique SNPs remaining
combined across arrays, genetic maps were created using the
Rutgers linkage-physical map v.2 [35] and converted from
Kosambi to Haldane distance.
Family Exclusions
We aimed to analyze white families without relationship errors
and without evidence of MMR deficiency. Self-reported family
structures were confirmed via evaluation of Mendelian inheritance
using PREST [36] and Pedcheck [37] based on SNP data. Where
probable sample switches or non-paternities were found, family
structures were altered (nine sibships changed to half-sibships) or
excluded (34 families excluded). We used EIGENSTRAT [38] to
estimate ethnicity for individuals with missing self-reported
ethnicity, verify ethnic similarity among related individuals, and
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exclude families with individuals clustering outside the large self-
reported white cluster (43 families were excluded, Figure S1).
MMR proficiency was evaluated using MSI testing, immuno-
histochemical (IHC) analysis, and LOD scores at known MMR
loci. MSI testing of Colon CFR and Newfoundland families was
performed on multiple family members using paired normal and
tumor DNA isolated from formalin-fixed, paraffin-embedded
(FFPE) material [39]. Ten markers were tested (mono-nucleotide
markers BAT25, BAT26, BAT34C4, and BAT40; di-nucleotide
markers ACTC, D5S346, D10S197, D17S250, and D18S55; and
complex repeat MYCL), and four unequivocal results were
required. Eighty-nine families with at least one MSI-H tumor
were excluded. IHC analysis of Colon CFR and Newfoundland
families for MLH1, MSH2, MSH6, and PMS2 expression was
performed on FFPE samples, as previously described [39]. IHC
staining across all sites was done at three centers, and pathologist
interpretation was conducted blind to MSI status. Forty-one
families in which at least one tumor showed protein loss were
excluded. Finally, we excluded an additional 15 families with
dominant LOD scores .0.4 within 20 kb surrounding MSH2,
MLH1, MSH6, PMS2, PMS1, MSH3, or MLH3 (linkage methods
described below). Thus, 356 white families with no evidence of
MMR deficiency were included in the analysis.
Linkage Analysis
Multipoint parametric and nonparametric linkage analyses used
MERLIN version 1.1.2 [40]; dominant and recessive models were
based on a prior segregation analysis (Table S2) [5]. Parametric
linkage in the presence of heterogeneity was assessed using
heterogeneity LOD (HLOD) scores, and the proportion of families
linked to each locus (a) was estimated using HOMOG [41]. Non-
parametric Kong & Cox LOD (NPL) scores from the linear model
were computed along with Sall statistics [42,43]. As has been useful
for other cancers [44,45], we sought to improve power by
increasing genetic homogeneity using family sub-groups defined a
priori based on presumed genetically relevant characteristics. Thus,
family groups were based on mean age at diagnosis (,50 years,
$50 years), ascertainment scheme (population-based, clinic-based,
or unknown), and number of affected individuals (2, 3, 4 or more).
Likelihood ratio testing evaluated heterogeneity of linkage across
the independent subsets of each subgroup factor (i.e., age at
diagnosis, ascertainment scheme, and number of affected individ-
uals).
Association Analysis
In key regions identified by linkage analysis, we also performed
association testing among an additional 1,136 cases (343 family
history positive and 793 family history negative cases with and
without 1st degree relative with CRC, respectively) and 997
controls from population-based collections of the Colon CFR who
were genotyped using the Illumina 1M/1M Duo SNP array, as
described previously [46]. Logistic regression estimated association
between genotype and CRC risk adjusted for age, gender, study
site, and four principal components representing ancestry [46]. A
quantile-quantile (Q-Q) plot of genome-wide observed versus
expected test statistics indicated no evidence of inflation (l=0.938)
[46].
Results
This collection of white CRC families with no evidence of
dMMR consisted of 277 families from the Colon CFR, 48 families
from the City of Hope consortium, and 31 families from
Newfoundland. A total of 1,612 individuals were successfully
genotyped including, on average, five individuals per family
(range, 2–10, mean 2.2 affected and 2.8 unaffected individuals).
The mean age at diagnosis was 59.7 years (range, 36–79) and 56.2
years (range, 31–74) among population- and clinic-based families,
respectively. The majority of families had two affected members
(56%) and an older (.50 years) mean age at diagnosis (84%). MSI
data were available on 224 families (209 MSS and 15 MSI-L), and
IHC data were available on 255 families and showed no evidence
of MMR deficiency (Table 1). Both MSI and IHC data were
available on 190 families. Sixty-seven families were not tested but
had a LOD,0.04 within 20 kb surrounding MSH2, MLH1,
MSH6, PMS2, PMS1, MSH3, or MLH3.
Genome-wide linkage scans of nine family groups were
conducted including analysis of all families and of subsets of
families defined by age, ascertainment scheme, and number of
affected individuals. Four regions in five family groups were
observed with HLOD scores greater than 3.0 (Figure 1). The
strongest result was based on analysis of 58 families with a mean
age at diagnosis ,50 years. In this group, we observed a dominant
HLOD of 4.51 on chromosome 4q21.1 (145.40 cM, NPL=2.52)
with an estimated 84% of families linked (Table 2). The peak
occurred at rs10518142 which is in intron 5 of NAAA encoding N-
acylethanolamine acid amidase. The linkage region, defined as a
1-HLOD support interval, spanned 16.0 cM (8.7 Mb). This peak
was not seen in older mean age at diagnosis families (Figure S2),
although significant heterogeneity by mean age at diagnosis was
not observed (LRT p=0.35). Other regions of interest in families
defined by age at diagnosis (HLOD.2.0) are provided in Table 3.
The second strongest linkage peak occurred in analysis of all
families (N=356) at 12q24.32 with a maximum dominant HLOD
of 3.60 (285.15 cM, NPL=2.88) and an estimated 48% of families
linked (Table 2). The peak SNP, rs952093, resides in intron 1 of
TMEM132C encoding transmembrane protein 132C; the equiv-
alent of a 1-HLOD interval defined a 14 cM (1.3 Mb) region.
Three suggestive regions in analysis of all families (HLOD.2.0)
were seen on chromosomes 4, 15, and 17 (Figure 1; Table 3),
including a region near to the 4q21.1 peak seen in younger age at
diagnosis families.
Additional linkage peaks with HLODs just over 3.0 were
observed on chromosome 15q22.31 (101.40 cM, rs1477798)
among 67 families with four or more affected individuals and
among 88 clinic-based families (Figure 1). Among families with at
least four affected members, a dominant HLOD of 3.07 was
observed (a=0.29, NPL= 1.03), and among clinic-based families
a dominant HLOD 3.03 was seen (a=0.32, NPL= 1.03). Thirty-
five families contributed to both analyses (i.e., clinic-based families
with four or more affected individuals) (Table 4); analysis of these
revealed a dominant HLOD of 3.15 (a=0.35, NPL= 1.88). Of
note, this region was also suggested by analysis of all families
(HLOD=2.51, a=0.20, Table 3). This peak was not seen in
analysis of smaller families, population-based families, or families
with unknown ascertainment, although significant heterogeneity
by family size or ascertainment scheme was not observed (all LRT
p’s.0.10). rs1477798 is in intron of MEGF11 which encodes
multiple EGF-like-domains 11.
An additional HLOD over 3.0 was observed in recessive
analysis of 200 families with only two affected family members
(Figure 1, Table 2). On 8q13.2, a recessive HLOD of 3.02 was
seen at rs1319036 (intron in pseudo-gene LOC100129096,
a=0.51, NPL= 0.08). Linkage assuming a recessive mode of
inheritance is consistent with an affected sibling pair family
structure. This region was not highlighted in analysis of larger
families (Table 3), although significant heterogeneity by family size
was not observed (LRT p=0.94). Another region of note is
Colon Linkage Study
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17q23.2 which revealed a dominant HLOD of 2.91 among all
families (143.49 cM, a=0.37) and dominant HLOD of 2.87
(143.50 cM, a=0.42) among 298 families with mean age of
diagnosis $50 years (Table 3); the peak SNP rs888115 is in intron
4 of MSI2 which encodes musashi homolog 2 (Drosophila).
Additional linkage results are provided in Figure S2. A second
recessive model linkage peak downstream of 8q13.2 was observed
in the same families with two affected members (HLOD=2.0,
a=0.51) on 8q12.2. These two nearby peaks were 11.2 cM
(8.1 Mb) apart.
Finally, we analyzed association within the 1-HLOD-support
intervals surrounding each linkage peak with HLOD.3.0 using
additional Colon CFR cases (N=1,176) and controls (N= 997). In
4q21.21, which showed evidence of linkage in younger age at
diagnosis families, the linkage SNP rs10518142 showed no
evidence of association; however, rs12643573, which is 2 cM
downstream, showed some evidence of association (OR 1.64,
p = 5.461025; family history positive OR 1.82, p= 1.061024)
(Figure S3). At rs1477798 in 15q22.31 which showed evidence of
linkage in clinic-based, larger families, a nominally significant case-
control association was observed (OR 1.16, p= 0.04) which was
modestly strengthened for cases with CRC family history (OR
1.24, p = 0.03); however, no significant difference in risk by family
history was observed and associations were far from genome-wide
significant. No other associations of note were observed.
Discussion
Results of this genome-wide linkage scan provide strong
evidence for four previously- unreported CRC susceptibility loci.
Notably, we identified a region at 4q21.1 among families with
younger mean age at diagnosis (dominant HLOD=4.51) and
estimated that 84% of these families were linked. The 1-HLOD-
support interval of this region, 16 cM (139 cM–155 cM) spanning
8.7 Mb, contains multiple known genes including NAAA. NAAA
encodes an N-acylethanolamine-hydrolyzing enzyme and is shown
to be expressed in variety of human tissues including colon [47].
Many of the genes upstream and downstream of NAAA are
members of the chemokine family that are clustered in 4q12-21
region. The CXC chemokines modulate tumor behavior by
regulation of angiogenesis, activation of a tumor-specific immune
response, and direct stimulation of tumor proliferation in an
autocrine or paracrine fashion [48].
Among all families, evidence for linkage was seen at 12q24.32
(HLOD=3.60) with an estimated 48% of families linked to this
locus (1-HLOD-support interval of 14 cM [276 cM–290 cM]
spanning 1.3 Mb). This region contains four known genes
(TMEM132C, SLC15A4, GLT1D1, and TMEM132D), four hypo-
thetical genes (LOC100128554, LOC387895, LOC440117, and
FLJ37505), and one microRNA (MIR3612). The four known
genes in this region are conserved in dog, mouse, and chicken and,
in some cases, zebrafish and Arabidopsis. One of these
transmembrane proteins (TMEM132D) is known to be expressed
in mature oligodendrocytes [49], but little else is known about
either function or pathology, as is also true of GLT1D1
(glycosyltransferase 1 domain containing 1) in humans. Members
of the SLC15 (solute carrier family 15) family are electrogenic
transporters of short-chain peptides into a variety of cells [50].
Evidence for linkage at 15q22.31, with a 1-HLOD-support
interval of 38 cM (78 cM–116 cM) spanning 12.9 Mb, was
particularly evident among families enrolled at high-risk clinics
or with four or more affected individuals (dominant
HLOD=3.15). This is a large gene-rich region and contains
many known genes including MEGF11 and RAB11A. Very little is
known about MEGF11 [51]. RAB11A is a RAS oncogene family
member expressed in tumor cell lines and suggested to be involved
in membrane trafficking [52]. Finally, among families with only
two affected individuals, the 1-HLOD-support interval of 12 cM
(126 cM–138 cM) spans 5 Mb (8q13.2, recessive HLOD=3.02)
and contains mostly pseudogenes. Notably, SULF1 in this region
has been suggested to modulate signaling by heparin-binding
growth factors, and downregulation represents a novel mechanism
by which cancer cells can enhance growth factor signaling [53].
Table 1. Characteristics of 356 White Colorectal Cancer Families with No Evidence of Defective Mismatch Repair, N (%).
Ascertainment Method
Population-based
N=189
Clinic-based
N=88
Unknowna
N=79
Mean Age of Diagnosis ,50 years 24 (13%) 19 (22%) 15 (19%)
$50 years 165 (87%) 69 (78%) 64 (81%)
Number of Affected Individuals 2 115 (61%) 26 (30%) 59 (75%)
3 51 (27%) 27 (31%) 11 (14%)
4–10 23 (12%) 35 (40%) 9 (11%)
MSIb MSS 119 (63%) 61 (69%) 29 (37%)
MSI-L 9 (5%) 6 (7%) 0
Unknownd 61 (32%) 21 (24%) 50 (63%)
IHC Expression of MMR Genesc No Loss 147 (78%) 77 (88%) 31 (39%)
Unknownd 42 (22%) 11 (13%) 48 (61%)
aAscertainment method not reported.
bMicrosatellite stability of the tumor; MSS indicates that the tumor was microsatellite stable; MSI-L indicates that the tumor had low microsatellite instability; Unknown
indicates that the tumor stability status was not available.
cMismatch repair status of the tumor by immunohistochemical analysis; No loss indicates that the tumor showed complete presence of protein expression of all the
MMR genes tested (MLH1, MSH2, MSH6, and PMS2); Unknown indicates that the tumor MMR-expression status was not available.
dUnknown for both MSI and IHC on 67 families is due to not being tested but had a LOD,0.04 within 20 kb surrounding MSH2, MLH1, MSH6, PMS2, PMS1, MSH3, or
MLH3.
doi:10.1371/journal.pone.0038175.t001
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Figure 1. Genome-wide Linkage Scans of White pMMR Family Groups with HLOD Score.3.0. HLOD scores from genome-wide linkage
scan of five white pMMR family subgroups. The blue line represents HLODs under the dominant model and the red line represents the HLODs under
the recessive model. Maximum observed HLODs.3.0 (in parenthesis) are labeled with the nearest SNP in four regions. (A) Family mean age at
Colon Linkage Study
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Like all complex diseases, CRC is heterogeneous and most likely
due to multiple partially penetrant susceptibility alleles as well as
non-genetic factors. In order to maximize power to detect linkage,
we sought to increase genetic homogeneity by grouping families
with similar, potentially genetically driven features, such as age at
diagnosis, clinic-based ascertainment, and number of affected
family members [5]. A number of other groups have taken a
similar predefined subset approach, reporting evidence of CRC
linkage in specific regions among family subsets [54]. Here, linked
regions on 4q21.1 and 8q13.2 become apparent only in the
families with younger mean age at diagnosis and only two affected
members, respectively, and the 15q22.31 peak suggested by
analysis of all families strengthened considering clinic-based or
large families only. Two observations provide particular reassur-
ance of the use of this subset approach: first, the subsets predicted
by segregation analysis to be more likely to be genetic (younger age
at diagnosis, clinic-based) showed greater evidence for linkage; and
second, the peak among smaller families (sibling pairs) was
identified using a recessive model.
Other CRC linkage scans have reported evidence of linkage at
3q21-24 and 9q22.2-31.2 in more than one study (Table S3) [18–
20,22–26,54]. Evidence of linkage on 3q was first reported in 12
large families with an HLOD score of 3.10 (NPL=3.40) [20],
followed by an independent study of 30 Swedish families at a
65 cM region flanked by markers D3S1558 and D3S3592 on
chromosome 3q13.31-27.1 overlapping with the earlier report
[24]. Another study that focused on MSS families specifically
showed evidence of linkage at this 3q region with an HLOD of
1.49 [26]. Wiesner et al [18] identified a linkage peak on
chromosome 9q22.2-31.2 region (p = 0.00045) in 53 MSS
kindreds in which at least two siblings were diagnosed with colon
cancer by age 64 or younger. Subsequently, the linkage peak,
flanked by markers D9S283 (80 cM) and D9S938 (104 cM), was
narrowed to 7.7 cM by three other studies [21,22,25]. In the
current study, we detected no linkage in this 9q22 region under
either dominant or recessive models. None of the other previously
published linkage regions (1p31.1, 4q31.3, 7q31.1, 15q14-22 and
17p13.3 [23,54]) showed evidence of linkage with HLOD of 2.0 or
higher in our study, although some regions harbored HLODs
close to 1.0 (Table S3).
A number of factors about this study are unique among CRC
genome-wide linkage-scans. First, ours is the largest study, thus
had higher power for detection. Second, our population included
only families with no evidence of MMR deficiency. Only two
smaller studies focused on pMMR families [18,26]. In this respect,
our approach of studying a large number of pMMR families
allowed us to identify specific linkage regions for this subgroup of
families who are known to differ clinically from dMMR families
and do not arise from MMR mutations [55–57]. Unlike some
prior studies, we included MSI-L families (N= 15) in our analysis,
because the relatedness of this phenotype to dMMR disease is
unknown; in all regions, results did not differ when analyses were
repeated exclusion of these families. Finally, the two most
significant regions reported here showed similar NPL scores in
these regions.
Several GWAS have reported highly replicated low-penetrance
loci [10–17], including a meta-analysis of ten independent studies
(11,067 cases and 12,517 controls) which replicated eight
previously-reported associations [46]. In relation to the four
linkage regions reported here, the closest reported GWAS
association is on chromosome 12q24 (rs7315438) [46] 3 Mb away
for our peak HLOD. It is not surprising that GWAS and linkage
analyses may identify different loci due to the complementary
strengths of each approach and the evidence, for many cancers,
that the familial and non-familial forms of the disease do not often
show affected pathways in common. This is largely supported by
our analysis of association within the linkage regions reported
here. In fact, despite the attractiveness of the two-hit hypothesis,
colorectal cancer is an important exception to the pattern among
adult cancers, rather than the rule: APC is central to a dominant
familial syndrome and frequently mutated somatically in the non-
familial disease [58]. There is a similar pattern involving the
MMR genes: they are mutated in the germline among those with
Lynch syndrome, and MLH1, at least, is frequently hyper-
methylated in the non-familial cancer.
In conclusion, these results suggest novel CRC susceptibility loci
on chromosomes 4q21, 8q13, 12q24, and 15q22. Further
confirmatory studies are needed, including targeted sequencing
and dense mapping of the identified linkage regions. Targeted
sequencing of these regions will facilitate identification of novel
variants that may be missed with linkage analysis, while fine-
mapping studies will narrow the region of interest to be examined.
In addition, pooling of linkage data across multiple genome-wide
scans should allow for fine-level analysis of discrepant results across
diagnosis ,50 years (N = 58). (B) All families (N = 356). (C) Families with four or more affected members (N = 67). (D) Clinic-based families (N = 88). (E)
Families with two affected members (N = 200).
doi:10.1371/journal.pone.0038175.g001
Table 2. Summary of Colorectal Cancer Linkage Results with HLOD Scores.3.0.
Family Group N Families Region
cM (Nearest
SNPa, Mbp)
Nearest Gene
(SNP location) Model HLOD (a) NPLc
Mean Age at
Diagnosis ,50
58 4q21.1 145.40 (rs10518142, 77.1) NAAA (intron) Dominant 4.51 (0.84) 2.52
All Families 356 12q24.32 285.15 (rs952093, 127.4) TMEM132C (intron) Dominant 3.60 (0.48) 2.88
4+ Affected 67 15q22.31 101.40 (rs1477798, 64.2) MEGF11 (intron) Dominant 3.07 (0.29) 1.03
Clinic-based 88 15q22.31 101.40 (rs1477798, 64.2) MEGF11 (intron) Dominant 3.03 (0.32) 0.98
2 Affected 200 8q13.2 132.52 (rs1319036, 70.3) LOC100129096b (intron) Recessive 3.02 (0.51) 0.08
aGenotyped SNP nearest to the peak of the linkage region; distances are reported in bp based on the NCBI build 36.2 and Haldane cM.
bPseudo-gene.
cNon-parametric Kong & Cox LOD.
doi:10.1371/journal.pone.0038175.t002
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Table 3. Summary of Colorectal Cancer Linkage Results with Maximum Observed HLOD Scores between 2.0 and 3.0.
Family Group
Linkage
Region cM (Nearest SNPa, Mbp) Nearest Gene
SNP Locationb
(distance, bp) Model HLOD (a)
All Families (N = 356) 4q21.21 154.41 (rs725826, 82.4) RASGEF1B 39 downstream (70,563) Dominant 2.29 (0.29)
15q22.31 101.40 (rs1477798, 64.2) MEGF11 intron Dominant 2.51 (0.20)
17q23.2 143.49 (rs888115, 53.0) MSI2 intron Dominant 2.91 (0.37)
Mean Age at
Diagnosis ,50 (N = 58)
12q24.32 277.56 (rs2013160, 126.3) LOC644489d 39 downstream (40,332) Dominant 2.86 (0.86)
14q32.1 161.58 (rs1956716, 94.0) SERPINA12 59 upstream (18,174) Recessive 2.68 (0.41)
22q11.21 7.92 (rs4269007, 16.7) MICAL3 intron Recessive 2.07 (0.24)
Mean Age at
Diagnosis $50 (N = 298)
15q22.33 106.55 (rs1822829, 65.3) AAGAB intron Dominant 2.66 (0.27)
17q23.2 143.50 (rs888115, 53.0) MSI2 intron Dominant 2.87 (0.42)
Population-based (N = 189) 7p14.1 89.98 (rs1949880, 39.0) POU6F2 intron Recessive 2.39 (0.38)
13q12.11 3.88 (rs264729, 21.1) LOC100128060d 39 downstream (4,619) Recessive 2.35 (0.40)
Clinic-based (N = 88) 1p21.3 217.34 (rs1144305, 96.3) LOC100132258d 59 upstream (207,801) Dominant 2.50 (0.51)
5q21.3 199.19 (rs1561350, 106.1) LOC345571d 59 upstream (231,963) Dominant 2.13 (0.23)
9q21.32 136.57 (rs918223, 85.6) GKAP1 intron Recessive 2.41 (0.32)
12q24.32 285.15 (rs952093, 127.4) LOC100132385d 39 downstream (77,728) Dominant 2.01 (0.38)
17q23.2 143.49 (rs888115, 53.0) MSI2 intron Dominant 2.58 (0.41)
Unknown Ascertainmentc
(N = 79)
13q13.3 46.30 (rs1170994, 35.5) DCLK1 intron Dominant 2.16 (1.00)
2 Affected (N = 200) 1q42.3 467.95 (rs1405633, 234.5) LOC343508 59 upstream (13,790) Dominant 2.12 (1.00)
6p25.3 2.63 (rs1055368, 852.0) EXOC2 59 upstream (214,441) Recessive 2.95 (0.52)
8q12.2 121.32 (rs1367972, 62.2) NPM1P6 5 upstream (111,467) Recessive 2.00 (0.51)
22q11.21 8.62 (rs387399, 16.8) MIR648 59 upstream (2,433) Recessive 2.42 (0.46)
3 Affected (N = 89) 5p14.1 77.05 (rs1966983, 31.8) PDZD2 59 upstream (53,152) Dominant 2.02 (0.73)
13q12-q13 8.88 (rs727081, 22.6) SGCG 59 upstream (22,892) Recessive 2.07 (0.49)
4+ Affected (N = 67) 12q24.32 285.16 (rs952093, 127.4) TMEM132C intron Dominant 2.28 (0.40)
14q24.3 110.11 (rs1125221, 74.0) TMEM90A 59 upstream (20,025) Recessive 2.03 (0.39)
17q23.1 147.11 (rs1296279, 55.3) TUBD1 intron Dominant 2.70 (0.36)
Xp11.3 119.99 (rs1375329, 43.8) LOC643167 39 downstream (23,566) Dominant 2.01 (0.41)
aGenotyped SNP nearest to the peak of the linkage region; distances are reported based on the NCBI build 36.2 and Haldane cM.
bSNP location and the distance in bp is given in regards to the nearest gene.
cAscertainment method not reported.
dPseudo-gene.
doi:10.1371/journal.pone.0038175.t003
Table 4. The overlap in the distribution of family groups.
Family Group
Mean Age at
Diagnosis ,50
Mean Age at
Diagnosis $50 Population-based Clinic-based 2 Affected 3 Affected 4+ Affected
Mean Age at
Diagnosis ,50
63 0 34 20 9 28 20
Mean Age at
Diagnosis $50
0 293 166 69 58 161 68
Population-based 34 166 200 0 0 115 26
Clinic-based 20 69 0 89 0 51 27
2 Affected 9 58 0 0 67 23 35
3 Affected 28 161 115 51 23 189 0
4+ Affected 20 68 26 27 35 0 88
doi:10.1371/journal.pone.0038175.t004
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family collections. It is clear from this work and the work of others
that multiple loci are involved in increasing susceptibility to CRC
in families and that family-based studies remain critical to the
identification and characterization of these loci.
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Family Groups with HLOD,3.0. Genome-wide linkage scans
of three white pMMR family groups with HLODS,3.0. The blue
line represents HLODs under the dominant model and the red
line represents the HLODs under the recessive model. (A) Family
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(N= 189). (D) Families with unknown ascertainment (N=79).
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rs10518142, the peak linkage SNP among families with younger
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principal components representing ancestry. The most significant-
ly associated SNP is a indicated by a purple diamond. Other than
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